Medication info
Crovon Tablet 5mg (Rosuvastatin Calcium)

Crovon Tablet 5mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daewon Biotech Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
28 tablets/box [14 tablets/PTP X 2]
Approval status
Active

MFDS item code 201906901 · Approved 2019.09.30 · Insurance code 057600300

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on administration of doses greater than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Daewon Biotech Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease

  • Hypercholesterolemia
  • dyslipidemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
  • stroke risk
  • myocardial infarction risk
  • risk of arterial revascularization
View approved original text

This medication is primarily used as an adjunct to dietary therapy for patients with hypercholesterolemia and mixed dyslipidemia. It is particularly effective for primary hypercholesterolemia and heterozygous familial hypercholesterolemia, lowering total cholesterol and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. Additionally, it is used adjunctively in patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia. It is also beneficial for pediatric patients aged 10 to 17 years who meet certain criteria for familial hypercholesterolemia. Furthermore, it contributes to reducing the risks of stroke, myocardial infarction, and arterial revascularization in high-risk groups with elevated cardiovascular disease risk. Overall, this medication is used to improve blood lipid levels and prevent cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on administration of doses greater than 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Adjust the dose at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. First, individuals allergic to any ingredients of this medication should not take it. Additionally, those with persistently elevated liver enzymes of unknown origin or severe liver dysfunction should not use this medication. Patients with muscle diseases or existing muscle issues should also avoid this medication. It should not be used in conjunction with the drug cyclosporine. Patients with severe renal impairment, particularly those with very diminished renal function, should not receive this medication. Women who are pregnant or breastfeeding, and women of childbearing age who are not using adequate contraception, should not take this medication, and women who may become pregnant can only use this medication when they are highly unlikely to conceive. Also, administering high doses (40mg) to patients prone to muscle diseases is prohibited. This includes those with moderate to severe renal impairment, hypothyroidism, patients with a family history of genetic muscle disorders, alcohol abusers, and those who are taking specific drugs in combination. Since this medication contains lactose, it should not be administered to patients with lactose intolerance or specific metabolic disorders. When taking this medication, caution should be taken in patients with a history of liver disease or those who consume alcohol excessively, and liver function tests should be performed repeatedly before and during treatment. Patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome must treat the underlying conditions first. Muscle-related side effects such as myalgia, myopathy, and rarely rhabdomyolysis have been reported, so if symptoms such as muscle pain, weakness, or cramps develop, the physician should be informed immediately. Especially if there is a significant rise in muscle enzyme levels in the blood, the use of this medication should be stopped. Muscle enzyme levels may increase due to exercise or other reasons, so care is needed during testing. In cases of severe renal failure or acute illness, this medication should be discontinued. Additionally, this medication can rarely cause severe muscle weakness or ocular myasthenia, and if these symptoms occur, the medication should be stopped. The risk of muscle side effects may increase when used in combination with other specific medications, so caution is necessary during co-administration. High-dose use may produce transient proteinuria, necessitating renal function testing. Asian patients may experience increased drug exposure, necessitating caution in dosing determination. In pediatric patients, limited reports have indicated effects on growth and secondary sexual characteristics. Common side effects while taking this medication include headache, dizziness, constipation, nausea, abdominal pain, itching, myalgia, weakness, hematuria, diarrhea, discomfort in the chest, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, joint pain, fatigue, numbness, sensory disturbances, cough, thrombocytopenia, amnesia, peripheral neuropathy, depression, sleep disturbances, sexual dysfunction, gynecomastia, memory decline, forgetfulness, confusion. Rarely, serious side effects such as pancreatitis, myositis, and rhabdomyolysis may occur. Abnormal liver function or changes in blood test values have also been reported, so regular monitoring is necessary during treatment. In both domestic and overseas post-marketing studies, serious adverse reactions related to the nervous system, respiratory system, skin, and blood have been rarely reported, requiring immediate consultation with medical personnel if such symptoms appear. This medication should not be used during pregnancy, and women who may become pregnant must use adequate contraceptive methods. It is also advisable for breastfeeding women not to take this medication. In case of overdose, there is no specific antidote, so treatment should be symptomatic, with careful observation of liver function and muscle enzyme levels. Dizziness may occur while taking this medication, necessitating caution while driving or operating machinery. Finally, this medication can interact with other drugs, so if taking other medications, it is crucial to inform medical personnel, particularly with medications that may increase the risk of muscle side effects.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, drug rash with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, ALT elevation, chest pain, muscle cramps, gout, erectile dysfunction, AST elevation, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, systemic pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

28 tablets/box [14 tablets/PTP X 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.